Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Trial of Zevaskyn (EB-101) for RDEB
NCT01263379Phase 2Completed
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Oct 2010
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of prademagene zamikeracel in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Abeona Therapeutics Inc.. Started Oct 2010; status: completed.
02
Drugs
prademagene zamikeracel
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT01263379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263379.